The stock of Tourmaline Bio Inc (TRML) has seen a -5.91% decrease in the past week, with a 41.21% gain in the past month, and a 65.35% flourish in the past quarter. The volatility ratio for the week is 7.30%, and the volatility levels for the past 30 days are at 7.47% for TRML. The simple moving average for the past 20 days is 1.85% for TRML’s stock, with a 10.41% simple moving average for the past 200 days.
Is It Worth Investing in Tourmaline Bio Inc (NASDAQ: TRML) Right Now?
Additionally, the 36-month beta value for TRML is 2.39. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TRML is 14.93M and currently, short sellers hold a 12.69% ratio of that float. The average trading volume of TRML on October 14, 2024 was 190.00K shares.
TRML) stock’s latest price update
Tourmaline Bio Inc (NASDAQ: TRML)’s stock price has dropped by -8.48 in relation to previous closing price of 27.48. Nevertheless, the company has seen a loss of -5.91% in its stock price over the last five trading days. seekingalpha.com reported 2024-10-13 that Tourmaline Bio’s Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by 2034. The company is also exploring Pacibekitug for atherosclerotic cardiovascular disease, with phase 2 TRANQUILITY study results anticipated in the first half of 2025.
Analysts’ Opinion of TRML
Many brokerage firms have already submitted their reports for TRML stocks, with Jefferies repeating the rating for TRML by listing it as a “Buy.” The predicted price for TRML in the upcoming period, according to Jefferies is $41 based on the research report published on December 15, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see TRML reach a price target of $48. The rating they have provided for TRML stocks is “Buy” according to the report published on December 04th, 2023.
Truist gave a rating of “Buy” to TRML, setting the target price at $43 in the report published on November 17th of the previous year.
TRML Trading at 30.45% from the 50-Day Moving Average
After a stumble in the market that brought TRML to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.94% of loss for the given period.
Volatility was left at 7.47%, however, over the last 30 days, the volatility rate increased by 7.30%, as shares surge +30.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.92% upper at present.
During the last 5 trading sessions, TRML fell by -5.91%, which changed the moving average for the period of 200-days by -8.45% in comparison to the 20-day moving average, which settled at $24.69. In addition, Tourmaline Bio Inc saw -3.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRML starting from Kulkarni Sandeep Chidambar, who purchase 1,779 shares at the price of $14.85 back on Aug 21 ’24. After this action, Kulkarni Sandeep Chidambar now owns 7,000 shares of Tourmaline Bio Inc, valued at $26,418 using the latest closing price.
Kulkarni Sandeep Chidambar, the CEO of Tourmaline Bio Inc, purchase 5,221 shares at $13.79 during a trade that took place back on Aug 16 ’24, which means that Kulkarni Sandeep Chidambar is holding 5,221 shares at $71,998 based on the most recent closing price.
Stock Fundamentals for TRML
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.39 for the gross margin
The net margin for Tourmaline Bio Inc stands at -15.68. The total capital return value is set at -0.13. Equity return is now at value -20.84, with -20.13 for asset returns.
Based on Tourmaline Bio Inc (TRML), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -143.18.
Currently, EBITDA for the company is -45.38 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of 252.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 46.87.
Conclusion
In conclusion, Tourmaline Bio Inc (TRML) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
